Contrasting Curis (NASDAQ:CRIS) and Gene Biotherapeutics (OTCMKTS:CRXM)

Gene Biotherapeutics (OTCMKTS:CRXM) and Curis (NASDAQ:CRIS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Gene Biotherapeutics and Curis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gene Biotherapeutics	0	0	0	0	0.00
Curis	0	0	3	0	3.00

Curis has a consensus price target of $21.00, indicating a potential upside of 919.42%. Given Curis’ stronger consensus rating and higher probable upside, analysts plainly believe Curis is more favorable than Gene Biotherapeutics.

Institutional and Insider Ownership

30.0% of Curis shares are owned by institutional investors. 49.8% of Gene Biotherapeutics shares are owned by company insiders. Comparatively, 5.5% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Gene Biotherapeutics and Curis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gene Biotherapeutics	N/A	N/A	N/A
Curis	-443.35%	-923.37%	-78.35%

Earnings & Valuation

This table compares Gene Biotherapeutics and Curis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gene Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Curis	$10.91 million	1.60	-$47.41 million	($7.03)	-0.29

Gene Biotherapeutics has higher earnings, but lower revenue than Curis.

Summary

Curis beats Gene Biotherapeutics on 5 of the 9 factors compared between the two stocks.

About Gene Biotherapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.